• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

葡萄膜黑色素瘤中缺乏BRAF突变。

Lack of BRAF mutations in uveal melanoma.

作者信息

Rimoldi Donata, Salvi Suzanne, Liénard Danielle, Lejeune Ferdy J, Speiser Daniel, Zografos Leonidas, Cerottini Jean-Charles

机构信息

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Switzerland.

出版信息

Cancer Res. 2003 Sep 15;63(18):5712-5.

PMID:14522889
Abstract

RAF proteins are serine/threonine kinases that mediate cellular responses to growth signals by activating the mitogen-activated protein kinase pathway. Mutations in the BRAF gene causing a V599E amino acid substitution that enhance the kinase activity have been described in >60% of cutaneous melanomas and premalignant melanocytic lesions. We have investigated the frequency of BRAF mutations at the expression level in melanomas of the uveal tract. None of the 30 metastases and 10 primary uveal melanomas tested expressed the V599E mutation. In contrast, this mutation was expressed by 65% of cutaneous melanoma samples, confirming previous results. In addition, a double mutation resulting in V599K substitution was detected in two suspect ocular metastases of cutaneous melanoma. Analysis of exon 11, the second common site of BRAF mutations, revealed only wild-type sequences in uveal melanomas. Analysis of tumor lysates showed the presence of phosphorylated mitogen-activated protein kinase, kinase, and mitogen-activated protein kinase in 50% of uveal and 100% of cutaneous melanoma metastases. Taken together, these results suggest that although the common BRAF mutations found in cutaneous melanoma do not play a role in tumorigenesis of uveal tract melanocytes, activation of the RAF/mitogen-activated protein kinase pathway may nevertheless play an important role in uveal melanoma.

摘要

RAF蛋白是丝氨酸/苏氨酸激酶,通过激活丝裂原活化蛋白激酶途径介导细胞对生长信号的反应。在超过60%的皮肤黑色素瘤和癌前黑素细胞病变中,已发现BRAF基因发生导致V599E氨基酸取代的突变,这种突变增强了激酶活性。我们研究了葡萄膜黑色素瘤中BRAF突变在表达水平上的频率。在检测的30个转移瘤和10个原发性葡萄膜黑色素瘤中,均未检测到V599E突变的表达。相比之下,65%的皮肤黑色素瘤样本表达了这种突变,证实了先前的结果。此外,在两例可疑的皮肤黑色素瘤眼转移瘤中检测到导致V599K取代的双突变。对BRAF突变的第二个常见位点外显子11的分析显示,葡萄膜黑色素瘤中仅存在野生型序列。对肿瘤裂解物的分析表明,50%的葡萄膜黑色素瘤转移瘤和100%的皮肤黑色素瘤转移瘤中存在磷酸化的丝裂原活化蛋白激酶、激酶和丝裂原活化蛋白激酶。综上所述,这些结果表明,尽管皮肤黑色素瘤中常见的BRAF突变在葡萄膜黑色素细胞的肿瘤发生中不起作用,但RAF/丝裂原活化蛋白激酶途径的激活在葡萄膜黑色素瘤中可能仍起着重要作用。

相似文献

1
Lack of BRAF mutations in uveal melanoma.葡萄膜黑色素瘤中缺乏BRAF突变。
Cancer Res. 2003 Sep 15;63(18):5712-5.
2
Absence of BRAF and NRAS mutations in uveal melanoma.葡萄膜黑色素瘤中BRAF和NRAS突变的缺失。
Cancer Res. 2003 Sep 15;63(18):5761-6.
3
Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.焦磷酸解反应检测原发性葡萄膜黑色素瘤中的B-RAF突变。
Invest Ophthalmol Vis Sci. 2008 Jan;49(1):23-7. doi: 10.1167/iovs.07-0722.
4
Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.丝裂原活化蛋白激酶(MAPK)信号通路的激活在葡萄膜黑色素瘤中是常见事件,尽管它很少通过BRAF或RAS的突变发生。
Br J Cancer. 2005 Jun 6;92(11):2032-8. doi: 10.1038/sj.bjc.6602598.
5
Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.与皮肤黑色素瘤相反,葡萄膜黑色素瘤中不存在BRAF基因突变。
Br J Cancer. 2003 May 6;88(9):1403-5. doi: 10.1038/sj.bjc.6600919.
6
BRAF mutations in conjunctival melanoma.结膜黑色素瘤中的BRAF突变
Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2484-8. doi: 10.1167/iovs.04-0093.
7
Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.皮肤黑色素瘤亚型显示出不同的BRAF和NRAS突变频率。
Clin Cancer Res. 2006 Aug 1;12(15):4499-505. doi: 10.1158/1078-0432.CCR-05-2447.
8
Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.丝裂原活化蛋白激酶通路在恶性黑色素瘤中的激活可以独立于 BRAF T1799A 突变发生。
Eur J Dermatol. 2010 Sep-Oct;20(5):575-9. doi: 10.1684/ejd.2010.1011. Epub 2010 Jul 7.
9
Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.转移性黑色素瘤组织中BRAF和N-RAS突变的分析
Cancer Res. 2003 Jul 15;63(14):3955-7.
10
SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.SPRY2是野生型BRAF黑色素细胞和黑色素瘤细胞中ras/细胞外信号调节激酶途径的抑制剂,但对V599E突变体则无此作用。
Cancer Res. 2004 Aug 15;64(16):5556-9. doi: 10.1158/0008-5472.CAN-04-1669.

引用本文的文献

1
State-of-the-art in Metastatic Uveal Melanoma Treatment: A 2025 Update : How to treat Metastatic Uveal Melanoma in 2025.转移性葡萄膜黑色素瘤治疗的最新进展:2025年更新版:如何在2025年治疗转移性葡萄膜黑色素瘤。
Curr Oncol Rep. 2025 May 17. doi: 10.1007/s11912-025-01684-0.
2
The role of circulating tumor DNA in melanomas of the uveal tract.循环肿瘤DNA在葡萄膜黑色素瘤中的作用。
Front Immunol. 2024 Dec 4;15:1509968. doi: 10.3389/fimmu.2024.1509968. eCollection 2024.
3
complexed with IGF2BP3 drives uveal melanoma progression via regulating N6-methyladenosine modification of .
与 IGF2BP3 复合可通过调节. 的 N6-甲基腺苷修饰来驱动葡萄膜黑色素瘤的进展。
Oncol Res. 2024 Apr 23;32(5):983-998. doi: 10.32604/or.2024.045972. eCollection 2024.
4
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis.免疫检查点抑制剂治疗转移性葡萄膜黑色素瘤的Meta 分析。
Sci Rep. 2024 Apr 3;14(1):7887. doi: 10.1038/s41598-024-55675-5.
5
Solitary Metastases Presentation from Uveal Melanoma: Report of 3 Cases and a Comprehensive Review of the Literature.葡萄膜黑色素瘤的孤立性转移表现:3例报告及文献综述
Ocul Oncol Pathol. 2023 Feb;8(4-6):203-210. doi: 10.1159/000527445. Epub 2022 Nov 10.
6
Primary Malignant Melanoma of the Oral Cavity: A Retrospective Study From a Tertiary Care Centre of North India.口腔原发性恶性黑色素瘤:来自印度北部一家三级护理中心的回顾性研究。
Cureus. 2022 Dec 17;14(12):e32621. doi: 10.7759/cureus.32621. eCollection 2022 Dec.
7
and Genes: A Comprehensive Review on Oncogenesis, Prognosis and Therapeutic Opportunities in Uveal Melanoma.以及《基因:葡萄膜黑色素瘤发生、预后及治疗机会的综合综述》
Cancers (Basel). 2022 Jun 22;14(13):3066. doi: 10.3390/cancers14133066.
8
Mutation spectrum in and in Chinese uveal melanoma.中国葡萄膜黑色素瘤中的突变谱。
Precis Clin Med. 2019 Dec;2(4):213-220. doi: 10.1093/pcmedi/pbz021. Epub 2019 Nov 13.
9
The future of targeted kinase inhibitors in melanoma.靶向激酶抑制剂在黑色素瘤中的未来。
Pharmacol Ther. 2022 Nov;239:108200. doi: 10.1016/j.pharmthera.2022.108200. Epub 2022 May 2.
10
Amelanotic melanoma of the palate: report of a case.腭部无黑色素性黑素瘤:病例报告。
BMJ Case Rep. 2022 Mar 30;15(3):e249027. doi: 10.1136/bcr-2022-249027.